Cagrilintide targets the amylin receptor, adding another satiety pathway on top of the three that retatrutide already activates
ii) Blood eosinophilia ( 1.5 103/L) or presence of atypical lymphocytes, and iii) Systemic involvement, including lymphadenopathy ( 2 cm in diameter), hepatitis (elevation of transaminases greater than twice the normal limit), interstitial nephritis, interstitial pneumonia, or carditis.2 However, this system is less sensitive in diagnosing less exuberant cases when compared to RegiSCAR
Presenters: Patrick Harrington, PhD Former SVP, Clinical Solutions and Strategic Partnering, WCG Manny Lazaro Senior Vice President, Clinical Development Operations, Kailera Therapuetics
Fatty Acid Modification# A defining structural feature of retatrutide is the C18 (octadecanedioic acid) fatty diacid moiety conjugated at Lys30 via a chemical linker